BioCentury | Jan 30, 2014
Cover Story

BBB-conquering antibodies

...bivalent binding preferentially led to lysosomal compartmentalization," said David Hilbert, CSO of cancer antibody company Zyngenia Inc....
...Basel, Switzerland University of California, San Francisco , Calif. University of Wisconsin-Madison , Madison, Wis. Zyngenia Inc....
BioCentury | Sep 2, 2013
Company News

Ambrx management update

...La Jolla, Calif. Business: Chemistry Hired: Peter Kiener as CSO, formerly president and CEO of Zyngenia Inc. WIR...
BioCentury | Mar 18, 2013
Clinical News

Zyngenia preclinical data

...In a mouse xenograft model of pancreatic cancer, Zyngenia's cetuximab-based bispecific zybody targeting EGFR and epidermal...
...IgG1 mAb targeting EGFR elsewhere, except in Japan where the 3 companies market the drug. Zyngenia Inc....
BioCentury | Mar 18, 2013
Clinical News

Zyngenia preclinical data

...In a mouse xenograft model of ovarian cancer, Zyngenia's trastuzumab-based bispecific zybody targeting angiopoietin 2...
...in the U.S., while Roche markets it elsewhere. Herceptin is a humanized mAb against EGFR2. Zyngenia Inc....
BioCentury | Jun 11, 2012
Company News

Zyngenia management update

...Interim CMO David Parkinson, who remains chairman of the clinical advisory board Zyngenia Inc. , Gaithersburg, Md...
BioCentury | Apr 30, 2012
Company News

Zyngenia management update

Zyngenia Inc. , Gaithersburg, Md. Business: Cancer, Autoimmune, Inflammation Hired: David Parkinson as a director and interim CMO, a newly created position, formerly president and CEO of Nodality Inc. WIR Staff autoimmune cancer Inflammation...
BioCentury | Dec 19, 2011
Company News

Zyngenia management update

Zyngenia Inc. , Gaithersburg, Md. Business: Cancer, Autoimmune, Inflammation Hired: Daniel Menichella as CBO, formerly SVP of corporate development and strategy at Talecris Biotherapeutics Inc. Promoted: David Hilbert to chief scientific officer and head of R&D...
BioCentury | May 23, 2011
Company News

Resolve Therapeutics board of directors update

...Resolve Therapeutics LLC , Kirkland, Wash. Business: Autoimmune Appointed: Peter Kiener, CEO of Zyngenia Inc. , as...
BioCentury | Sep 13, 2010
Financial News

Zyngenia financial update

...Associates participated in the extension. Zyngenia raised $10 million in the round in November 2009. Zyngenia Inc....
BioCentury | Sep 9, 2010
Financial News

Zyngenia raises $15 million

...the total raised to $25 million. Existing investor New Enterprise Associates participated in the extension. Zyngenia...
Items per page:
1 - 10 of 15
BioCentury | Jan 30, 2014
Cover Story

BBB-conquering antibodies

...bivalent binding preferentially led to lysosomal compartmentalization," said David Hilbert, CSO of cancer antibody company Zyngenia Inc....
...Basel, Switzerland University of California, San Francisco , Calif. University of Wisconsin-Madison , Madison, Wis. Zyngenia Inc....
BioCentury | Sep 2, 2013
Company News

Ambrx management update

...La Jolla, Calif. Business: Chemistry Hired: Peter Kiener as CSO, formerly president and CEO of Zyngenia Inc. WIR...
BioCentury | Mar 18, 2013
Clinical News

Zyngenia preclinical data

...In a mouse xenograft model of pancreatic cancer, Zyngenia's cetuximab-based bispecific zybody targeting EGFR and epidermal...
...IgG1 mAb targeting EGFR elsewhere, except in Japan where the 3 companies market the drug. Zyngenia Inc....
BioCentury | Mar 18, 2013
Clinical News

Zyngenia preclinical data

...In a mouse xenograft model of ovarian cancer, Zyngenia's trastuzumab-based bispecific zybody targeting angiopoietin 2...
...in the U.S., while Roche markets it elsewhere. Herceptin is a humanized mAb against EGFR2. Zyngenia Inc....
BioCentury | Jun 11, 2012
Company News

Zyngenia management update

...Interim CMO David Parkinson, who remains chairman of the clinical advisory board Zyngenia Inc. , Gaithersburg, Md...
BioCentury | Apr 30, 2012
Company News

Zyngenia management update

Zyngenia Inc. , Gaithersburg, Md. Business: Cancer, Autoimmune, Inflammation Hired: David Parkinson as a director and interim CMO, a newly created position, formerly president and CEO of Nodality Inc. WIR Staff autoimmune cancer Inflammation...
BioCentury | Dec 19, 2011
Company News

Zyngenia management update

Zyngenia Inc. , Gaithersburg, Md. Business: Cancer, Autoimmune, Inflammation Hired: Daniel Menichella as CBO, formerly SVP of corporate development and strategy at Talecris Biotherapeutics Inc. Promoted: David Hilbert to chief scientific officer and head of R&D...
BioCentury | May 23, 2011
Company News

Resolve Therapeutics board of directors update

...Resolve Therapeutics LLC , Kirkland, Wash. Business: Autoimmune Appointed: Peter Kiener, CEO of Zyngenia Inc. , as...
BioCentury | Sep 13, 2010
Financial News

Zyngenia financial update

...Associates participated in the extension. Zyngenia raised $10 million in the round in November 2009. Zyngenia Inc....
BioCentury | Sep 9, 2010
Financial News

Zyngenia raises $15 million

...the total raised to $25 million. Existing investor New Enterprise Associates participated in the extension. Zyngenia...
Items per page:
1 - 10 of 15